## Noriaki Tabata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4106555/publications.pdf

Version: 2024-02-01

		471509	580821
75	855	17	25
papers	citations	h-index	g-index
75	75	75	1242
75	75	75	1242
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1285-1294.	2.0	7
2	Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study. Cardiovascular Intervention and Therapeutics, 2022, 37, 66-77.	2.3	19
3	Early response of right-ventricular function to percutaneous mitral valve repair. Clinical Research in Cardiology, 2022, 111, 859-868.	3.3	5
4	Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS). Heart and Vessels, 2022, , 1.	1.2	2
5	Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1227-1235.	2.6	4
6	Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010895.	3.9	34
7	Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. Journal of Cardiology, 2022, 80, 56-63.	1.9	3
8	Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. ESC Heart Failure, 2022, 9, 1976-1986.	3.1	6
9	Disparities in transcatheter mitral valve repair - Disparities being corrected little by little?. International Journal of Cardiology, 2022, 352, 52-53.	1.7	O
10	A simple staging system using biomarkers for wildâ€type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2022, 9, 1731-1739.	3.1	5
11	Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovascular Intervention and Therapeutics, 2021, 36, 81-90.	2.3	24
12	Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2021, 325, 121-126.	1.7	9
13	Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair. Clinical Research in Cardiology, 2021, 110, 440-450.	3.3	8
14	Risk modeling in transcatheter aortic valve replacement remains unsolved: an external validation study in 2946 German patients. Clinical Research in Cardiology, 2021, 110, 368-376.	3.3	12
15	QRS duration is a risk indicator of adverse outcomes after MitraClip. Catheterization and Cardiovascular Interventions, 2021, 98, E594-E601.	1.7	O
16	Successful Aortic Valve-in-Valve Implantation in a Patient With Replaced Aorta, Subclavian Artery Occlusions and Aortic Dissection. Circulation Journal, 2021, 85, 314.	1.6	1
17	Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention Thrombosis Research, 2021, 200, 141-148.	1.7	6
18	The predictive value of intraprocedural mitral gradient for outcomes after MitraClip and its periâ€interventional dynamics. Echocardiography, 2021, 38, 1115-1124.	0.9	3

#	Article	IF	CITATIONS
19	Prognostic significance of liver stiffness assessed by fibrosisâ€4 index in patients with heart failure. ESC Heart Failure, 2021, 8, 3809-3821.	3.1	9
20	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1578-1590.	2.9	18
21	Prognostic value of left atrial strain in patients with wildâ€type transthyretin amyloid cardiomyopathy. ESC Heart Failure, 2021, 8, 5316-5326.	3.1	9
22	Percutaneous interventions for mitral and tricuspid heart valve diseases. Cardiovascular Intervention and Therapeutics, 2020, 35, 62-71.	2.3	18
23	Association of heart failure duration with clinical outcomes after transcatheter mitral valve repair for functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2020, 98, E412-E419.	1.7	1
24	Usefulness of relative apical longitudinal strain index to predict positive <sup>99m</sup> Tcâ€labeled pyrophosphate scintigraphy findings in advancedâ€age patients with suspected transthyretin amyloid cardiomyopathy. Echocardiography, 2020, 37, 1774-1783.	0.9	9
25	Quantification of Myocardial Extracellular Volume With Planning Computed Tomography for Transcatheter Aortic Valve Replacement to Identify Occult Cardiac Amyloidosis in Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Imaging, 2020, 13, e010358.	2.6	17
26	Safety and Efficacy of Protamine Administration for Prevention of BleedingÂComplications in Patients Undergoing TAVR. JACC: Cardiovascular Interventions, 2020, 13, 1471-1480.	2.9	28
27	Cytotoxin-associated gene-A-seropositivity and Interleukin-1 polymorphisms influence adverse cardiovascular events. IJC Heart and Vasculature, 2020, 27, 100498.	1.1	2
28	Impact of combined baseline and postprocedural troponin values on clinical outcome following the MitraClip procedure. Catheterization and Cardiovascular Interventions, 2020, 96, E735-E743.	1.7	1
29	Prognostic impact of cancer history in patients undergoing transcatheter aortic valve implantation. Clinical Research in Cardiology, 2020, 109, 1243-1250.	3.3	11
30	Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture. Hemodialysis International, 2020, 24, 202-211.	0.9	8
31	Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. Clinical Research in Cardiology, 2020, 109, 1165-1176.	3.3	10
32	Newer Specific Risk Scores for Outcome After Transcatheter Aortic Valve Replacement. Circulation Journal, 2019, 83, 1630-1632.	1.6	1
33	Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation $\hat{a}\in$ " The ATTRACTIVE-TTAS study. IJC Heart and Vasculature, 2019, 23, 100346.	1.1	3
34	Current status and future perspective of structural heart disease intervention. Journal of Cardiology, 2019, 74, 1-12.	1.9	27
35	Risk Factors and Prevalence of Deep Vein Thrombosis After the 2016 Kumamoto Earthquakes. Circulation Journal, 2019, 83, 1342-1348.	1.6	27
36	Predictive Value of the Platelet-to-Lymphocyte Ratio in Cancer Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: CardioOncology, 2019, 1, 159-169.	4.0	3

#	Article	IF	CITATIONS
37	Combined Percutaneous Therapy for Tricuspid Regurgitation Using the Cardioband and PASCAL System inÂ1ÂProcedure. JACC: Cardiovascular Interventions, 2019, 12, e197-e198.	2.9	3
38	Impact of the Leaflet-to-Annulus Index on Residual Mitral Regurgitation in Patients Undergoing Edge-to-Edge Mitral Repair. JACC: Cardiovascular Interventions, 2019, 12, 2462-2472.	2.9	26
39	Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 290-300.	4.0	53
40	Evaluation of Collateral Source Characteristics With 3â€Dimensional Analysis Using Micro–Xâ€Ray Computed Tomography. Journal of the American Heart Association, 2018, 7, .	3.7	2
41	Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup. Journal of Cardiology, 2017, 69, 103-109.	1.9	4
42	Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertension Research, 2017, 40, 423-428.	2.7	25
43	CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. IJC Heart and Vasculature, 2017, 15, 15-20.	1.1	9
44	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	21
45	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis, 2017, 260, 116-120.	0.8	33
46	Prognostic Value of the CHADS <sub>2</sub> Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation—A Multiâ€Center Observational Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	17
47	Relationship between asymptomatic intra-cranial lesions and brachial-ankle pulse wave velocity in coronary artery disease patients without stroke. Hypertension Research, 2017, 40, 392-398.	2.7	13
48	Antithrombotic Regimens in Patients Undergoing Transcatheter Aortic Valve Implantation. Circulation Journal, 2017, 81, 308-309.	1.6	1
49	The dawn of a new era in onco-cardiology: The Kumamoto Classification. International Journal of Cardiology, 2016, 220, 837-841.	1.7	12
50	Clinical and morphological presentations of acute coronary syndrome without coronary plaque rupture $\hat{a}\in$ " An intravascular ultrasound study. International Journal of Cardiology, 2016, 220, 112-115.	1.7	2
51	Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1409-H1415.	3.2	12
52	Helicobacter Pylori-seropositivity along with genetic and environmental factors predicts clinical outcome after acute coronary syndrome. International Journal of Cardiology, 2016, 212, 54-56.	1.7	2
53	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. Journal of the American Heart Association, $2016, 5, .$	3.7	51
54	Prognostic significance of circulating leukocyte subtype counts in patients with coronary artery disease. Atherosclerosis, 2016, 255, 210-216.	0.8	28

#	Article	IF	CITATIONS
55	Prevalence of coronary macro- and micro-vascular dysfunctions after drug-eluting stent implantation without in-stent restenosis. International Journal of Cardiology, 2016, 222, 185-194.	1.7	16
56	Unprotected left main intervention for surgery-ineligible patients with coronary artery diseaseâ€"Usefulness of micro-CT images for stent. International Journal of Cardiology, 2016, 221, 385-389.	1.7	3
57	The real-world prevalence of cardiovascular events related to coronary spasm after percutaneous coronary intervention. Journal of Cardiology, 2016, 68, 20-28.	1.9	4
58	Changes in the risk factors for coronary spasm. IJC Heart and Vasculature, 2016, 12, 85-87.	1.1	4
59	Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. International Journal of Cardiology, 2016, 220, 328-332.	1.7	26
60	Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1494-H1500.	3.2	13
61	Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. Journal of Cardiology, 2016, 67, 104-109.	1.9	9
62	Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients. Heart and Vessels, 2016, 31, 1038-1044.	1.2	5
63	Clinical characteristics and intravascular ultrasound findings of culprit lesions in elderly patients with acute coronary syndrome. Heart and Vessels, 2016, 31, 341-350.	1.2	4
64	Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0166240.	2.5	19
65	Distribution of Ankle-Brachial Index among Inpatients with Cardiovascular Disease: Analysis Using the Kumamoto University Hospital Medical Database. Annals of Vascular Diseases, 2016, 9, 22-29.	0.5	4
66	Physiological basis of discordance between coronary flow velocity reserve and hyperemic microvascular resistance for evaluating coronary microvascular dysfunction in patients without atherosclerotic obstruction. International Journal of Cardiology, 2015, 201, 535-537.	1.7	6
67	High incidence of coronary spasm after percutaneous coronary interventions. International Journal of Cardiology, 2015, 182, 171-173.	1.7	12
68	Single-wire pressure and flow velocity measurement for quantifying microvascular dysfunction in patients with coronary vasospastic angina. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H478-H484.	3.2	28
69	Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thrombosis Research, 2015, 135, 1081-1086.	1.7	7
70	Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event. International Journal of Cardiology, 2015, 187, 231-233.	1.7	2
71	Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. International Journal of Cardiology, 2015, 187, 411-413.	1.7	8
72	Gender differences in impact of vascular endothelial dysfunction on clinical outcome following coronary stenting in patients with coronary heart disease. International Journal of Cardiology, 2014, 177, 723-725.	1.7	2

#	Article	IF	CITATIONS
73	A case of human immunodeficiency virus-related heart failure resembling dilated cardiomyopathy but accompanied by high cardiac output. Journal of Cardiology Cases, 2014, 10, 167-170.	0.5	O
74	Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thrombosis Research, 2014, 134, 939-944.	1.7	18
75	Management of intra-aortic balloon counterpulsation by argatroban anticoagulation in a patient with a history of heparin-induced thrombocytopenia. Journal of Cardiology Cases, 2012, 6, e154-e157.	0.5	1